Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

TransThera Bioscience, a Nanjing Startup, Raises $10 Million from Morningside

publication date: Oct 13, 2016
TransThera Biosciences, a Nanjing biotech startup, raised $10 million in an A Round financing that was led by Morningside Ventures of Hong Kong. TransThera is built on an open innovation model that seeks to develop novel NCE drugs. Its current portfolio addresses oncology, cardiovascular diseases and other therapeutic areas. The company was founded (and is led) by Dr. Frank Wu, who was previously CEO of XuanZhu Pharma, a drug discovery subsidiary of Sihuan Pharma. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital